NCT06386094Recruiting
Cardiac Dysfunction in Patients with Fatty Liver Disease
Cirrhotic Cardiomyopathy and Cardiac Dysfunction in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease
Source: ClinicalTrials.gov · Last updated 29 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and/or altered diastolic relaxation with electrophysiological abnormalities, in absence of known cardiac disease. Left ventricular diastolic dysfunction (LVDD) is associated with risk of hepatorenal syndrome (HRS) , septic shock. , heart failure in the perioperative period following liver transplantation, and after trans-jugular intrahepatic portosystemic shunt (TIPS) insertion . The echocardiographic E/e' ratio is a predictor of survival in LVDD, with multiple studies, including prospective data from our Centre. The inability of the heart to cope with stress or sepsis induced circulatory failure is a key concept of the increased mortality risk due to LVDD. In view of the metabolic syndrome and diabetes epidemic and an increasing number of patients being diagnosed with non-alcoholic fatty liver disease, there is increased risk of developing cardiac dysfunction due to multiple comorbidities including coronary artery disease, hypertensive heart disease, cirrhotic cardiomyopathy, which are contributors to overall cardiovascular risk of mortality.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 19 Sept 2023
- Start date
- 15 Jul 2023
- Primary completion date
- 15 Aug 2027
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- NCT number
- NCT06386094
What you commit to
- Study type: Observational
- Planned participants: 150
- From 15 Jul 2023 to the primary completion date, 15 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Chronic renal disease
- Hypertension
- Valvular heart disease
- Sick sinus syndrome/ Pacemaker
- Cardiac rhythm disorder
- Portal vein thrombosis
Age
- Age \>65 years
Other
- Pregnancy and peripartum cardiomyopathy
- Hypothyroidism
- Hyperthyroidism
- Transjugular intrahepatic porto systemic shunt (TIPS) insertion
- Hepatocellular carcinoma
- Anemia Hb \< 8gm/dl in females, and \< 9 gm/dl in males at the time of assessment
Who the study is looking for
- Age range of 18-65 years
- metabolic dysfunction associated steatotic liver disease as diagnosed either by histology or clinical, laboratory, non invasive tests, USG findings and vibration controlled transient elastography (VCTE).
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dr. Madhumita Premkumar Coordinator of this site? Confirm its status | Chandigarh | India | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.